The 2025 Black Book of Physician Practice Management Technology Released: A Competitive Intelligence Report 
VITAS® Healthcare Unveils Inpatient Hospice Unit at Lee Memorial Hospital
The home-like facility in Southwest Florida is expected to serve 400+ patients each yearFORT MYERS, Fla., Dec. 18, 2024 (GLOBE...
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
Key preclinical milestone for novel, non-opioid extended-release pain therapeutic SARASOTA, FL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc....
Mesoblast to be Added to Nasdaq Biotechnology Index
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
Streamline Health® Expands Presence In Texas with 400-Bed Health System for RevID
Oracle Health partnership enables 400-bed Texas-based health system to leverage RevID’s automated charge reconciliation to improve financial performanceATLANTA, Dec. 18,...
Photys Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Induced Proximity PHICS Technology for Cardiometabolic Diseases
Partnership leverages proprietary PHICS™ technology to bring together a kinase and target of interest to modulate protein function, in this...
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1...
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies
- Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials...
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering...
NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology
NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational...
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform...
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel...
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease
CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate...
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has...
Redecan Cannabis Launches New Limited-Edition Genetics and Expands Signature ‘Wrapped & Redee’ Pre-roll Line for the Holidays
TORONTO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Redecan Cannabis, a leading brand under Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a...
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
Company debt reduced by $194 millionCash position after closing will be in excess of $180 million DANBURY, Conn. and WESTLAKE...
Positive results advance peanut tablet to phase II development
ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding...
Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease
Investments of up to $50 million from the Bill & Melinda Gates Foundation to develop globally accessible in vivo genetic...
Polyrizon’s Moving Forward with Expected 2025 Clinical Trial – Entered Manufacturing Agreement for its PL-14 Allergy Blocker
The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer...
Vireo Growth Inc. Announces $75 Million Financing and Acquisitions of Four Single State Operators
– $75 million equity financing at $0.625 per Vireo share will result in combined new entity having an industry-leading balance...
The Ensign Group Agrees to Add Its First Operations in Alaska and Oregon And Announces Expansion in Washington and California
SAN JUAN CAPISTRANO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group...